Silodosin

• Description:

  Silodosin (KAD 3213; KMD 3213) is a potent, selective and orally active α1A-adrenergic receptor (α1A-AR) blocker. Silodosin exhibits high affinity for α1A-AR (Ki=0.036 nM), over 162-fold and 50-fold than for α1B-AR and α1D-AR with Ki values of 21 nM and 2.0 nM, respectively. Silodosin is an effective and well-tolerated agent, it can be used for the investigation of LUTS/BPH[1][3].

• Product Name Alternative:

  KAD 3213; KMD 3213

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H373

• Target:

  Adrenergic Receptor; Bacterial

• Type:

  Reference compound

• Related Pathways:

  Anti-infection; GPCR/G Protein; Neuronal Signaling

• Field of Research:

  Cancer; Endocrinology

• Assay Protocol:

  https://www.medchemexpress.com/Silodosin.html

• Purity:

  99.82

• Solubility:

  DMSO : ≥ 50 mg/mL

• Smiles:

  O=C (N) C1=CC (C[C@@H] (C) NCCOC2=CC=CC=C2OCC (F) (F) F) =CC3=C1N (CC3) CCCO

• Molecular Formula:

  C25H32F3N3O4

• Molecular Weight:

  495.53

• Precautions:

  H302, H373

• References & Citations:

  [1]Maxime Rossi , Silodosin in the treatment of benign prostatic hyperplasia. Drug Des Devel Ther. 2010; 4: 291–297.|[2]Villa L, et al. Effects by silodosin on the partially obstructed rat ureter in vivo and on human and rat isolated ureters.Br J Pharmacol. 2013 May;169 (1) :230-8.|[3]Osman NI, et al.Silodosin : a new subtype selective alpha-1 antagonist for the treatment of lower urinary tract symptoms in patients with benign prostatic hyperplasia.Expert Opin Pharmacother. 2012 Oct;13 (14) :2085-96.|[4]Kawahara T, et al. Silodosin inhibits the growth of bladder cancer cells and enhances the cytotoxic activity of cisplatin via ELK1 inactivation.Am J Cancer Res. 2015 Sep 15;5 (10) :2959-68. eCollection 2015.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Launched

• CAS Number:

  160970-54-7